TheraRadar
← Back
Data updated: Mar 29, 2026

UBI

OncologyInfectious DiseaseImmunology
Generics

UBI is a generic drug manufacturer focused on Oncology, Infectious Disease, Immunology.

2020
Since
4
Drugs
-
Trials
78
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

OLANZAPINE 2026-02-09
Labeling
OLANZAPINE 2026-02-09
Labeling
OLANZAPINE 2026-01-23
OLANZAPINE 2026-01-22
Labeling
OLANZAPINE 2026-01-06
Labeling
OLANZAPINE 2026-01-06
Labeling
OLANZAPINE 2025-12-03
Labeling
OLANZAPINE 2025-12-02
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 57%
1 drugs Phase 3: 3 Phase 2: 8 Phase 1: 30
Infectious Disease 20%
1 drugs Phase 3: 2 Phase 2: 1 Phase 1: 6
Immunology 12%
0 drugs Phase 2: 4 Phase 1: 5
Gastroenterology 8%
0 drugs Phase 2: 3 Phase 1: 3
Dermatology 4%
0 drugs Phase 3: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Infectious Disease, Dermatology, Immunology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Infectious Disease
COSETTE other
Dermatology, Infectious Disease, Immunology, Oncology
Merck big-pharma
Oncology, Infectious Disease, Immunology
Baxter specialty
Infectious Disease, Oncology, Dermatology